### PATENT COOPERATION TREATY

## **PCT**

REC'D	1	2	JUL	2005
WIPO				PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

App	licant's or agent's file	reference						
	ACH63183WO00		FOR FURTHER ACTION		See Form PCT/IPEA/416			
		International filing date 30.07.2004	(day/month/year)	Priority date (day/month/year) 30.07.2003				
Inte	mational Patent Clas	sification (IPC) or	national classification and I	PC				
A6:	1K9/107, A61K9/	12, A61K9/48						
App	licant							
	SPERSE LIMITEI	)						
1.	riamonty ander	THE SO AND US	ansinimed to the applicar	it according to Article	this International Preliminary Examining			
2.	This REPORT c	This REPORT consists of a total of sheets, including this cover sheet.						
3.			by ANNEXES, comprising					
	a. $\square$ sent to th	e applicant and	to the International Bure	au) a total of sheets	s, as follows:			
	aria,	ts of the descrip or sheets contair inistrative Instruc	III IU I ECUIICANDIIS AIIINNN	ngs which have beer zed by this Authority	n amended and are the basis of this report (see Rule 70.16 and Section 607 of the			
	☐ shee beyo	ts which superse	ede earlier sheets, hut w	hich this Authority co lication as filed, as i	onsiders contain an amendment that goes ndicated in item 4 of Box No. I and the			
	Cup	nomental box.						
	sequence		bureau only) a total of (ii bles related thereto, in o e Listing (see Section 80		nber of electronic carrier(s)) , containing a rm only, as indicated in the Supplemental ve Instructions).			
4.	This report conta	ains indications r	relating to the following it	ems:				
	Box No. I	Basis of the op	pinion					
	☐ Box No. II	Priority						
1	☐ Box No. III	Non-establishr	ment of opinion with rega	ard to novelty, inventi	ve step and industrial applicability			
	☐ Box No. IV	Lack of unity o	f invention	and the state of t	to step and industrial applicability			
	☑ Box No. V	Reasoned stat	ement under Article 35(2 tations and explanations	2) with regard to nove supporting such sta	elty, inventive step or industrial			
	☐ Box No. VI	Certain docum		, promission of the	.cmore			
	☐ Box No. VII	Certain defects	s in the international app	lication				
	☐ Box No. VIII	Certain observ	rations on the internation	al application				
Date	Date of submission of the demand			Date of completion o	f this report			
13.	13.05.2005			13.07.2005				
Nan	Name and mailing address of the international			Authorized Officer				
prei	preliminary examining authority:				and Turbes Polantany			
European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas			Bas	Boulois, D	ž <b>M</b>			
-	Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016			Telephone No. +31 7	0 340 3878			
L				10, 431 /	O 100-040 0			

# INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/003329

_	Box	No. I Basis of the report					
1.	Witl filed	ith regard to the <b>language</b> , this report is based on the international application in the language in which it was ed, unless otherwise indicated under this item.					
		This report is based on translations from the original language into the following language, which is the language of a translation furnished for the purposes of:  international search (under Rules 12.3 and 23.1(b))  publication of the international application (under Rule 12.4) international preliminary examination (under Rules 55.2 and/or 55.3)					
2.	2. With regard to the elements* of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):						
	Des	cription, Pages					
	1-26	as originally filed					
	Clai	ms, Numbers					
	1-22	as originally filed					
		a sequence listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing					
3.		The amendments have resulted in the cancellation of:  the description, pages the claims, Nos. the drawings, sheets/figs the sequence listing (specify): any table(s) related to sequence listing (specify):					
4.	□ had Sup	This report has been established as if (some of) the amendments annexed to this report and listed below not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the plemental Box (Rule 70.2(c)).  the description, pages the claims, Nos.  the drawings, sheets/figs the sequence listing (specify):  any table(s) related to sequence listing (specify):					
	*	If item 4 applies, some or all of these sheets may be marked "superseded."					

## INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/GB2004/003329

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1-22

1. Statement

Novelty (N)

Yes: Claims

5-8, 10, 11, 18-20

No: Claims

1-4, 9, 12-17, 21, 22

Inventive step (IS)

Yes: Claims

5-8, 10, 11, 18-20

No: Claims

1-4, 9, 12-17, 21, 22

Industrial applicability (IA)

Yes: Claims

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

#### Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Reference is made to the following documents:

D1: US-A-4 999 198 (BARNETT ET AL) 12 March 1991 (1991-03-12)

D2: WO 97/32559 A (DISPERSE TECHNOLOGIES LIMITED; WHEELER, DEREK, ALFRED) 12 September 1997 (1997-09-12)

2. The present application does not meet the criteria of Article 33(1) PCT, because the subject-matter of claims 1-4, 9, 12-17, 21, 22 is not new in the sense of Article 33(2) PCT.

The document D1 discloses the preparation of drug delivery systems in polyaphrons form (see D1, col. 2, I. 23-46). The drug used in D1 is scopolamine. The description of the present application discloses on pages 9-13 a list of drugs presented as "poorly water soluble drugs". A great proportion of these are in faci water soluble (for instance all salts). Scopolamine has therefore to be considered also as porly water soluble drug. The hydrophilic phase disclosed in D1 is clearly comprised between 1 and 20% by weight, since col. 2 lines 23-42 dsicloses the presence of 5 ml of a hydrophilic phase, which is the foam.

Consequently, the subject-matter of claims 1-4, 9, 12-17, 21, 22 is not new over D1 ( Article 33(2) PCT ).

3. The documents D1 and D2 appear to be of particular relevance as far as inventive step is concerned (Article 33(3) PCT). These documents solve indeed the same problem, namely making compositions in form of biliquid foam, but for topical or transdermal forms. The problem of the present application being to make delivery forms adapted to oral delivery, the present application, as far as novel subject-matter is concerned, is considered to be inventive over D1 or D2 (Article 33(3) PCT).